Eli Lilly is officially capping its insulin prices at $35 a month, the company announced this week.
Effective in the coming months, the drugmaker will be slashing its prices for its non-branded insulin, its blockbuster insulin Humalog and a newly launched biosimilar, Rezvoglar, by at least 70%.
For it’s non-branded insulin, the company will be selling the vials at $25 each, making it the lowest list-priced mealtime insulin available. Humalog, its most prescribed insulin, will see a price reduction of 70%. As for the newly launched Rezvoglar, it will be sold for $92 per five pack, offering a 78% discount to its reference biologic, Lantus. The price changes will be effective immediately for those patients purchasing insulin out of pocket or without commercial insurance.
In 2019, Eli Lilly was hit with a subpoena from the New York Attorney General’s Office over the pricing and sales of its insulin treatment, and asked for more transparency on pricing and the obstacles to providing more affordable insulin. The company's recent move also follows on the heels of French drugmaker Sanofi, who announced last year that it would also offer any of its insulins for a total of $35 for a 30-day supply.
